IRC-082451

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

1.	Aron Badin, Romina: 1 article (01/2013)
2.	Auguet, Michel: 1 article (01/2013)
3.	Bertrand, Anne: 1 article (01/2013)
4.	Boulet, Sabrina: 1 article (01/2013)
5.	Brouillet, Emmanuel: 1 article (01/2013)
6.	Chabrier, Pierre-Etienne: 1 article (01/2013)
7.	Dollé, Frédéric: 1 article (01/2013)
8.	Gaillard, Marie-Claude: 1 article (01/2013)
9.	Guillermier, Martine: 1 article (01/2013)
10.	Hantraye, Philippe: 1 article (01/2013)

1.	Dyskinesias (Dyskinesia) 01/01/2013 - "A dose-dependent efficacy of IRC-082451 against dyskinesias was observed. " 01/01/2013 - "This study aimed at evaluating the effect of IRC-082451 (base of BN82451), a novel multitargeting hybrid molecule, on L-DOPA-induced dyskinesias (LIDs) and hypolocomotor activity in a non-human primate model of PD. " 01/01/2013 - "IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates."
2.	Neuroinflammatory Diseases 01/01/2013 - "IRC-082451 displays multiple properties: it inhibits neuronal excitotoxicity (sodium channel blocker), oxidative stress (antioxidant) and neuroinflammation (cyclooxygenase inhibitor) and is endowed with mitochondrial protective properties. "

1.	Levodopa (L Dopa)
2.	BN82451
3.	Sodium Channel Blockers
4.	Cyclooxygenase Inhibitors
5.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
6.	Antioxidants